NEW YORK, March 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ:
KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem
Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals,
Inc. (NASDAQ: SNSS). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.AnalystsReview.com/register
--
Hospira Inc. Analyst Notes
On March 4, 2014, Hospira Inc.
(Hospira) announced the appointment of David J. Endicott as President, Hospira Medical
Devices, with effect from March 10,
2014. According to Hospira, in this role, Endicott will be
responsible for establishing a fully integrated device organization
- leading the commercial, research and development, manufacturing
and related support functions to continue to advance the Company's
product pipeline, execute its device strategy and ultimately drive
global growth. F. Michael Ball, CEO
of Hospira, commented, "David is an accomplished global leader with
more than 25 years of industry experience - 15+ of those where I
had the privilege of working with him directly and had an
opportunity to see firsthand his proven ability to define,
implement and manage sustainable process, organizational and
cultural change. With his impressive track record in delivering
strong results across all business functions, we're confident David
will successfully lead our dual imperatives to execute our device
strategy and drive global growth." The full analyst notes on
Hospira Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03112014/HSP/report.pdf
--
Karyopharm Therapeutics, Inc. Analyst
Notes
On March 5, 2014, Karyopharm
Therapeutics, Inc. (Karyopharm) released its full-year 2013 results
and provided an update on its clinical development plans.
Karyopharm registered revenues of $0.4
million, down 39.0% YoY. The Company posted an annual net
loss of $33.9 million, compared to a
net loss of $15.9 million in
full-year 2012. Diluted net loss came in at $5.59 per share, compared to diluted net loss of
$8.95 per share in full-year 2012.
Michael Kauffman, Karyopharm CEO,
said, "2013 was has been a very important year for Karyopharm,
highlighted by robust clinical development activity focused on our
novel, first in class, orally active selective inhibitors of
nuclear export compounds, also called SINEs." Commenting on its
future plans, Kauffman said, "We have moved rapidly from discovery
to the clinic. In 2014, we plan to initiate three
registration-directed trials in hematological indications and to
continue to broaden our solid tumor development activity. This
foundation positions us to continue our broad-based development
plan to assess the breadth of this novel anti-cancer mechanism."
The full analyst notes on Karyopharm Therapeutics, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03112014/KPTI/report.pdf
--
Revance Therapeutics, Inc. Analyst
Notes
On March 5, 2014, Revance
Therapeutics, Inc. (Revance) announced the appointment of
Angus C. Russell as Chairman of the
Board, effective immediately. Commenting on this, Dan Browne, President and CEO of Revance, said,
"Angus' impressive track record in the global biopharmaceutical
industry will bring significant value to Revance and its Board of
Directors." Browne added, "With his extensive experience growing
companies commercially, I am thrilled to have him as a partner as
we continue to execute and build our business." The full analyst
notes on Revance Therapeutics, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03112014/RVNC/report.pdf
--
Pluristem Therapeutics, Inc. Analyst
Notes
On March 6, 2014, Pluristem
Therapeutics, Inc. (Pluristem) announced that the US Food and Drug
Administration (FDA) has reviewed the Company's comparability
studies of its PLacental eXpanded (PLX) cell products and granted
approval for the manufacturing of these products in its new
commercial-scale cell manufacturing facility - which has the
ability to efficiently produce approximately150,000 doses of PLX
cells annually. Zami Aberman,
Chairman and CEO of Pluristem, stated, "Knowing that the 'Process
is the Product' in cell therapy, we have established our leadership
position in the industry by focusing on our 3D commercial scale
cell manufacturing processes. To be a successful company in the
industry, we believe it is imperative to possess and control the
manufacturing processes we have developed at Pluristem. We believe
this FDA approval, combined with the approval given by the
Paul-Ehrlich-Institute (PEI) of Germany announced on January 23, 2014, is an indication that these
regulatory bodies see our proprietary 3D manufacturing process as a
valid and sustainable commercial scale solution for potential cell
therapies." The full analyst notes on Pluristem Therapeutics, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03112014/PSTI/report.pdf
--
Sunesis Pharmaceuticals, Inc. Analyst
Notes
On March 6, 2014, Sunesis
Pharmaceuticals, Inc. (Sunesis) released its Q4 2013 and full year
2013 results. During the quarter, Sunesis registered total revenues
of $2.0 million, flat as compared to
Q4 2012, while full-year 2013 reported total revenues stood at
$8.0 million, up 111.9% YoY. The
Company posted quarterly net loss of $7.2
million, compared to net loss of $4.1
million in Q4 2012, and annual net loss of $34.6 million, compared to net loss of
$44.0 million in full year 2012.
Further, Sunesis reported quarterly diluted net loss of
$0.15 per share, compared to diluted
net loss of $0.20 per share in Q4
2012, and annual diluted net loss of $0.66 per share, compared to diluted net loss of
$0.91 per share in full year 2012.
The full analyst notes on Sunesis Pharmaceuticals, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03112014/SNSS/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance@AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review